Cannabis use and risk of psychosis, an etiological link?;Cannabis et troubles psychotiques, quel lien étiologique?

Presse Medicale

Volumn 33, Issue 8, 2004, Pages 551-554

  Verdoux, Hélène ^a,b   Tournier, Marie ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CENTRE HOSPITALIER CHARLES PERRENS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS;

ADOLESCENCE; ADOLESCENT; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; HUMAN; MENTAL HEALTH; PROSPECTIVE STUDY; PSYCHOSIS; REVIEW; RISK FACTOR; SELF MEDICATION;

EID: 2342504610     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(04)98663-0     Document Type: Short Survey

References (18)

1. Expertise collective Inserm. Cannabis. Quels effets sur le comportement et la santé? Paris, Inserm, 2001.
2. Degenhardt L, Hall W. The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychol Med 2001; 31: 659-68.
3. Verdoux H, Liraud F, Gonzales B, Assens F, Abalan F, van Os J. Suicidality and substance misuse in first-admitted subjects with psychotic disorder. Acta Psychiatr Scand 1999; 100: 389-95.
4. Hambrecht M, Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry 2000; 34: 468-75.
5. Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association? Br J Psychiatry 1990; 157: 25-33.
6. Tramèr M, Carroll D, Campbell F, Reynolds D, Moore R, McQuay H. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323: 16.
7. Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen J. Cannabis Use and the Expression of Psychosis Vulnerability in Daily Life. Psychol Med 2003; 33: 23-32.
8. Tennant FS, Jr., Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry 1972; 27: 133-6.
9. Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483-6.
10. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002; 325: 1199.
11. Van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002; 156: 319-27.
12. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002; 325: 1212-13.
13. Tanda G, Pontieri F, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common m1 opoid receptor mechanism. Science 1997; 276: 2048-50.
14. Gorritti MA, Rodriguez de Fonseca F, Navarro M, Palomo T. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. Eur J Pharmacol 1999; 365: 133-42.
15. McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 1995; 15: 277-81.
16. Choquet M, Hassler C, Ledoux S. Alcool, tabac, cannabis et autres drogues illicites parmi les élèves des collèges et des lycées. Espad 1999. Paris, Inserm/OFDT, 2001.
17. Observatoire français des drogues et des toxicomanies. Drogues et dépendances. Indicateurs et tendances 2002. Paris, OFDT, 2002.
18. Rose G. The strategy of preventive medicine. Oxford, Oxford University Press, 1992.